- Rating
- 2
- Confidence
- 2
- Informativeness
- 1
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
This paper presents iGC, a two-stage framework for antibody optimization. It first learns an SHM mutation prior from B-cell lineage data and adapts it to the target dataset. It then applies KL-regularized reinforcement learning with a Reward–Tax Meta-Gradient objective to improve antigen binding while maintaining mutation diversity. The experiments evaluate mutation prediction, cumulative DMS reward, and mutation diversity.
Critical strengths
-
Effective use of existing data. The framework combines repertoire-derived parent–child pairs with affinity-labeled mutation trajectories. This allows abundant mutation data to support prior learning while using more limited experimental binding measurements for optimization.
-
Biologically motivated formulation. Separating mutation generation from affinity-driven selection corresponds naturally to the diversification–selection cycle of affinity maturation. Regularizing the policy toward an SHM prior also provides a reasonable mechanism for retaining biologically plausible mutation preferences.
Critical weaknesses
-
Limited methodological novelty. The framework primarily integrates established components. RTMG itself builds on prior intrinsic-reward meta-learning. While the application is relevant, the paper does not sufficiently establish a distinct algorithmic contribution beyond combining and adapting these techniques to antibody optimization.
-
Risk of overfitting to the reward proxy. Although RTMG reshapes the training reward, both affinity supervision and the principal evaluation in Table 2 rely on the same DMS scoring landscape. Candidates are ranked and evaluated using cumulative DMS reward, so improvements may reflect increasingly effective exploitation of this fixed proxy rather than corresponding improvements in actual binding.
-
Insufficient validation of additive scoring for generated multi-mutants. Section 4.2 computes trajectory rewards by summing single-mutant DMS effects, ignoring epistatic interactions. Consequently, individually beneficial substitutions may receive a favorable combined score even when their combination compromises binding. The original GCReplay study provides experimental support for additivity within this antibody system, but this does not establish its accuracy for the combinations actively selected by iGC. The evaluation therefore remains an insufficiently validated proxy for the actual affinity of novel multi-mutant candidates.
Questions for authors
-
DMS coverage and missing-score handling. What fraction of generated substitutions has a directly available DMS score, broken down by method and mutation budget? How are substitutions absent from the lookup table handled? The released scoring script appears to assign zero to missing entries, please confirm whether this rule was used for Table 2.
-
SHMReplay’s higher diversity and compatibility with RTMG. Table 2 shows consistently higher mutation diversity for SHMReplay than for iGC. What explains this gap, given RTMG’s explicit goal of preventing diversity collapse? Could the proposed affinity-guided optimization and Reward–Tax objective be applied to SHMReplay under matched data and generation budgets? Such a comparison would clarify whether combining SHMReplay’s broader exploration with the proposed optimization yields a better reward–diversity trade-off, and whether the gains depend on the mutation model used by iGC.